Drug Trial Radar · NCT05581719
A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy
Last checked: Nov 19, 2026Latest source record: Apr 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
14
Actual
Start
Nov 15, 2022
Primary completion
Apr 15, 2024
Study completion Apr 15, 2024
Sponsor
- Lead sponsor
- Enlivex Therapeutics RDO Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, non-randomized, multicenter, Phase 1/2a study to evaluate the safety and potential efficacy of Allocetra-OTS in the treatment of advanced solid tumor malignancy as monotherapy or in combination with an anti-PD-1 therapy.
Conditions
- Solid Tumor
- Peritoneal Metastases
- Peritoneal Cancer
Interventions
Allocetra-OTSDrug
Allocetra-OTS is a cell-based therapy consisting of non-HLA matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state.
NivolumabDrug
Immune checkpoint inhibitor (anti-PD-1 antibody)
TislelizumabDrug
Immune checkpoint inhibitor (anti-PD-1 antibody)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of Allocetra-OTSTime frame: 3-5 weeks
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Rambam Medical Center
Haifa, Israel
Hadassah Medical Center
Jerusalem, Israel
Sheba Medical Center
Ramat Gan, Israel
Sourasky Medical Center
Tel Aviv, Israel
Clínica Universidad de Navarra
Madrid, Spain
NEXT Madrid
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.